Industry News

• Pfizer discontinues a Phase 3 study of figitumumab  Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
  Pfizer Inc. March 11, 2010  
• Two Phase 3 trials of sunitinib did not meet the primary endpoint  Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
  Pfizer Inc. March 11, 2010  
• NxStage(R) secures $15 million revolving line of credit  NxStage Medical announced that it has secured a two-year $15 million revolving line of credit from Silicon Valley Bank. The revolving line of credit is subject to a borrowing base of trade accounts receivable, inventory and field equipment.
  NxStage Medical, Inc. March 11, 2010  
• Abbott seeks FDA approval of a new six-month 45-mg formulation of Lupron(R) Depot  The U.S. Food and Drug Administration(FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron(R) Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.
  Abbott March 11, 2010  
• Cordis unveils next generation CoCr coronary stent  Cordis Corporation announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances.
  Johnson & Johnson March 11, 2010  
• Generex receives positive responses from independent physicians and nurse practitioners  Generex Biotechnology announced that Health Management Resources (HMR) has recently conducted two focus groups in Indianapolis for Generex Oral-lyn(TM).
  Generex Biotechnology Corporation March 11, 2010  
• NMT Medical announces completion of eight-member Scientific Advisory Board  NMT Medical announced the completion of its Scientific Advisory Board (SAB), which is composed of eight industry leading experts from the cardiovascular and neurological medical communities.
  NMT Medical, Inc. March 11, 2010  
• Synta Pharmaceuticals reports fourth quarter and full year 2009 financial results  In the fourth quarter of 2009, Synta recognized total collaboration revenue of $4.7 million compared to net revenue of $0.6 million for the same period in 2008. Total collaboration revenue was $144.2 million for the year ended December 31, 2009.
  Synta Pharmaceuticals, Inc. March 11, 2010  
• Dr. Francis S. Collins receives Albany Medical Center Prize  NIH Director Francis S. Collins, M.D., Ph.D. has been named a recipient of the Albany Medical Center Prize in Medicine and Biomedical Research for his leading role in mapping the human genome.
  National Institutes of Health March 10, 2010  
• Ischemix moves prevention drug to Phase 2a trials  Maynard biotechnology firm Ischemix has begun a Phase 2a trial of its cardio-protective drug, CMX-2043. The drug candidate is intended to prevent peri-operative ischemia-reperfusion injury in patients following percutaneous coronary intervention (PCI) procedures.
  Mass High Tech March 10, 2010  

   (next 10 articles)